Increasing Efficiency in Protein and Cell Production by Combining Single-Use Bioreactor Technology and Perfusion - An off-the-shelf, single-use perfusion system. - BioPharm International

ADVERTISEMENT

Increasing Efficiency in Protein and Cell Production by Combining Single-Use Bioreactor Technology and Perfusion
An off-the-shelf, single-use perfusion system.


BioPharm International Supplements
Volume 24, Issue 5, pp. s4-s11

CELL PROPAGATION AND BIOREACTOR INOCULATION

A Per.C6 cell line expressing a monoclonal anti–EpCAM (epithelial cell adhesion molecule, a cancer marker) immunoglobulin G (IgG) antibody (licensed from Crucell) and commercially available, chemically-defined serum-free medium, CDM4 PerMab (Hyclone), was used for the batch and perfusion phases of the cultivation. Inoculum was produced in two 1 L polycarbonate Erlenmeyer flasks (Corning) with 300 mL culture, each incubated in a Certomat CT plus shaker incubator (Sartorius Stedim Biotech) at 85% humidity, 37 C, 5% CO2 and a shaker rate of 240 rpm.

The bioreactor bag (CultiBag RM10 perfusion, Sartorius Stedim Biotech), equipped with single-use optical pH and DO probes, was filled with 5 L of medium and equilibrated to process temperature. After calibration of the optical sensors, the reactor was inoculated with a seeding density of 5 x 105 cells/mL. The initial process parameters were 19 rocks/min, a rocking angle of 6 and a temperature of 37 C. The pH was controlled at pH 7.1 with CO2 and 1M Na2CO3. Dissolved oxygen (DO) was controlled at 40% by automatically adjusting the gas flow rate (range 0.3 to 3 L/min) and the composition of N2, air, and O2. For comparison to the perfusion process, a batch culture was performed using the above mentioned parameters.

CONTROL OF THE PERFUSION PROCESS

An empty bag was welded to the perfusion outlet of the bioreactor bag, and a 50 L media bag was welded to the perfusion inlet and placed on a balance. Perfusion was started at an exchange rate of 0.5 reactor volumes/d, which corresponds to a feed and harvest flow of 0.105 kg/h. The perfusion rate was subsequently increased based on the measured glucose and glutamine concentration as detailed below. As the bioreactor controller automatically increased the gas flow rate and oxygen content in the process gas, the angle and rocking rate were adjusted manually from initially 6 to 10, and 19 rocks/min to 23 rocks/min. Due to the increased angle and rocking rate, oxygen transfer from the headspace to the liquid phase could be further improved.

Samples were taken at regular intervals for offline pH measurement (Sartorius PB-11 pH meter) and monitored for cell count (Nucleocounter, Sartorius Stedim Biotech), glucose, glutamine, and lactate concentration (Bioprofile 100plus Analyzer, Nova Biomedical) and antibody concentration (ELISA).

HIGH CELL DENSITY CULTIVATION OF AN ANTIBODY EXPRESSING CELL LINE


Figure 1: Viable cell density and viability of batch and perfusion process.
In batch mode, a cell density of 17 106 cells/mL at a viability of 98% was reached (see Figure 1). This result is typical for a pH and DO controlled bioreactor batch culture of this specific Per.C6 clone and the PerMAB medium used. Once the substrate was depleted, cells went into the stationary phase. In contrast, in an uncontrolled process, e.g., in a shaker flask, the cell density typically reaches about 12 106 cells/mL under similar conditions (data not shown).

In perfusion culture using the BIOSTAT CultiBag RM 20, we were able to reach a very high cell density of 150 106 cells/mL at a viability of 99%. Up to now, the highest reported cell density of a wave-type, single-use bioreactor has been 60 106 cells/mL (7). Typically, we achieve about a 10-fold higher cell density in perfusion culture using this bioreactor set up compared to the batch results (data not shown). The total cell yield was 7.5 1011 cells derived from 5 L of reactor culture.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
FDA Develops Alternative Assay to Increase Availability of Influenza Vaccines
April 10, 2014
Merck Announes Management Changes
April 7, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here